ATXS
Price
$12.43
Change
-$0.12 (-0.96%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
710.14M
111 days until earnings call
Intraday BUY SELL Signals
RGNX
Price
$11.64
Change
+$0.04 (+0.34%)
Updated
Nov 13 closing price
Capitalization
589.25M
109 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATXS vs RGNX

Header iconATXS vs RGNX Comparison
Open Charts ATXS vs RGNXBanner chart's image
Astria Therapeutics
Price$12.43
Change-$0.12 (-0.96%)
Volume$10.02K
Capitalization710.14M
REGENXBIO
Price$11.64
Change+$0.04 (+0.34%)
Volume$561.03K
Capitalization589.25M
ATXS vs RGNX Comparison Chart in %
ATXS
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATXS vs. RGNX commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and RGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ATXS: $12.55 vs. RGNX: $11.60)
Brand notoriety: ATXS and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 76% vs. RGNX: 92%
Market capitalization -- ATXS: $710.14M vs. RGNX: $589.25M
ATXS [@Biotechnology] is valued at $710.14M. RGNX’s [@Biotechnology] market capitalization is $589.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 2 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • ATXS’s TA Score: 2 bullish, 6 bearish.
  • RGNX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а -0.55% price change this week, while RGNX (@Biotechnology) price change was -0.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

ATXS is expected to report earnings on Mar 05, 2026.

RGNX is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($710M) has a higher market cap than RGNX($589M). RGNX YTD gains are higher at: 50.065 vs. ATXS (40.380). RGNX (-129.93M) and ATXS (-131.42M) have comparable annual earnings (EBITDA) . RGNX has more cash in the bank: 323M vs. ATXS (259M). ATXS has less debt than RGNX: ATXS (4.77M) vs RGNX (77.7M). RGNX has higher revenues than ATXS: RGNX (156M) vs ATXS (0).
ATXSRGNXATXS / RGNX
Capitalization710M589M121%
EBITDA-131.42M-129.93M101%
Gain YTD40.38050.06581%
P/E RatioN/AN/A-
Revenue0156M-
Total Cash259M323M80%
Total Debt4.77M77.7M6%
FUNDAMENTALS RATINGS
ATXS vs RGNX: Fundamental Ratings
ATXS
RGNX
OUTLOOK RATING
1..100
9170
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
3543
P/E GROWTH RATING
1..100
10017
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (54) in the Biotechnology industry is in the same range as RGNX (72). This means that ATXS’s stock grew similarly to RGNX’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that ATXS’s stock grew similarly to RGNX’s over the last 12 months.

ATXS's SMR Rating (97) in the Biotechnology industry is in the same range as RGNX (97). This means that ATXS’s stock grew similarly to RGNX’s over the last 12 months.

ATXS's Price Growth Rating (35) in the Biotechnology industry is in the same range as RGNX (43). This means that ATXS’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (17) in the Biotechnology industry is significantly better than the same rating for ATXS (100). This means that RGNX’s stock grew significantly faster than ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSRGNX
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 7 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SESGX26.330.11
+0.42%
Sit ESG Growth S
TVLIX12.900.02
+0.16%
Touchstone Value Institutional
MRGGX45.340.04
+0.09%
MFS Core Equity R1
ADGAX27.150.02
+0.07%
AB Core Opportunities A
GRMRX31.640.02
+0.06%
Nationwide S&P 500 Index R

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with SYRE. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+0.32%
SYRE - ATXS
50%
Loosely correlated
+0.34%
XENE - ATXS
49%
Loosely correlated
-0.60%
RGNX - ATXS
47%
Loosely correlated
+0.43%
ORKA - ATXS
46%
Loosely correlated
+0.35%
DNLI - ATXS
46%
Loosely correlated
-0.34%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+0.43%
SYRE - RGNX
56%
Loosely correlated
+0.34%
DNLI - RGNX
55%
Loosely correlated
-0.34%
BEAM - RGNX
54%
Loosely correlated
-2.71%
VYGR - RGNX
54%
Loosely correlated
-0.23%
MGNX - RGNX
53%
Loosely correlated
-3.29%
More